Zevra Therapeutics, INC

Zevra Therapeutics stockholders elected directors and ratified auditors, but failed to pass a proposal to declassify the Board.

Zevra Therapeutics announced a significant increase in Q1 2026 net revenue to $36.2 million, driven by MIPLYFFA performance and a $50 million portfolio sale, resulting in a strong cash position and debt-free balance sheet.

Zevra Therapeutics has sold its SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million, simultaneously resolving a pending lawsuit and repaying its $63 million term loan.

Zevra Therapeutics announced the appointment of Timothy Sangiovanni as interim principal financial officer, effective January 1, 2026.

Zevra Therapeutics announced the appointment of Alicia Secor to its Board of Directors and the retirement of Wendy Dixon, PhD, effective December 2, 2025.

Zevra Therapeutics announced the resignation of its Chief Financial Officer, R. LaDuane Clifton, effective December 31, 2025, as the company initiates a search for his successor.

Zevra Therapeutics reports Q1 2026 net income of $37.9 million, bolstered by a $43.3 million gain from the sale of its SDX portfolio assets.

Zevra Therapeutics reported a significant increase in revenue and a swing to net income for the nine months ended September 30, 2025, driven by strong MIPLYFFA sales and a $148.3 million PRV sale, despite an impairment charge for OLPRUVA.

Zevra Therapeutics posted a significant net income increase in Q2 2025, driven by a $148.3 million Priority Review Voucher sale, despite an impairment charge on its OLPRUVA asset and ongoing operational losses.

Zevra Therapeutics completes the sale of its Priority Review Voucher for $150 million and reports a net loss of $3.1 million for Q1 2025, driven by increased product revenue and strategic cost management.

Zevra Therapeutics reports a net loss of $33.2 million for the third quarter of 2024, alongside updates on its commercial and clinical programs.

Zevra Therapeutics reports a net loss of $19.9 million for the second quarter of 2024, alongside updates on its pipeline and commercial activities.

Zevra Therapeutics' 2024 10-K filing highlights the FDA approval and commercial launch of MIPLYFFA, along with financial results and strategic shifts towards rare disease focus.

Zevra Therapeutics details its capital structure, outstanding warrants, and anti-takeover provisions in a recent SEC filing, providing investors with a comprehensive overview of its securities.

Tamara A. Favorito, a Director at Zevra Therapeutics, Inc., has been granted 30,000 stock options as compensation for her board service.

Zevra Therapeutics, Inc. reports the grant of stock options to Director Alicia Secor as compensation for her board service.

Corey Michael Watton, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options as compensation for his board service.

Douglas W. Calder, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options as compensation for his board service.

Zevra Therapeutics, Inc. reports the grant of 30,000 stock options to Director Thomas Anderson as compensation for board service.

Rahsaan Thompson, Chief Legal & Compliance Officer at Zevra Therapeutics, Inc., reported a transaction involving the acquisition of 1,794 shares of common stock.

Zevra Therapeutics announces its 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, and board declassification.

All three leading proxy advisory firms recommend Zevra stockholders vote for the company's director nominees and withhold on dissident nominees at the upcoming Annual Meeting.

Zevra Therapeutics urges stockholders to vote for its nominees amidst a proxy battle with an activist investor, highlighting its recent achievements and strategic plan.

Daniel J. Mangless is soliciting proxies to elect two new directors to Zevra Therapeutics' board, aiming to address what he views as poor governance and excessive executive compensation.

Zevra Therapeutics files its definitive proxy statement for the 2025 annual meeting, advocating for the re-election of Tamara Favorito and Wendy Dixon, Ph.D. to the Board and addressing alternative director nominees.

Zevra Therapeutics files its definitive proxy statement, urging stockholders to vote for its director nominees to defend board independence against a 2.8% stockholder seeking to gain majority control.

Vanguard Capital Management has reported beneficial ownership of 5.11% of Zevra Therapeutics Inc. common stock as of June 30, 2026.

FMR LLC, along with Abigail P. Johnson, has reported beneficial ownership of 5.5% of Zevra Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Zevra Therapeutics Inc. following an internal realignment.

Woodline Partners LP has reported a 6.2% beneficial ownership stake in Zevra Therapeutics, Inc., holding 3,476,143 shares of common stock.

Adage Capital Management, L.P. and its principals have filed an amended Schedule 13G, reporting a 3.96% beneficial ownership stake in Zevra Therapeutics, Inc. as of September 30, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.38% in Zevra Therapeutics, Inc. as of December 31, 2024.